mRNA Manufacturing: Market Size & Forecast 2026

The global mRNA manufacturing market sits at approximately USD 12.5 billion in 2025 (base year), recovering from the COVID-19 vaccine demand peak through a structurally different demand composition. Cancer immunotherapy, protein replacement therapies, and gene-editing delivery now collectively represent 39% of end-use demand, offsetting the 38% COVID-19 share that still anchors the category. The 2026-2032 CAGR of 13.8% implies a 2032 market size of roughly USD 30.9 billion, but anyone who has covered this market since 2021 knows the consensus trajectory has been reset twice already. The dominant supply-side tension is feedstock concentration: fewer than 10 qualified suppliers produce cGMP-grade nucleoside triphosphates (NTPs) and proprietary ionizable lipids at commercial scale, creating structural switching costs that buyers cannot engineer away in a 12-month window.

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.